Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$19.56 USD

19.56
791,320

-0.39 (-1.95%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $19.57 +0.01 (0.05%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why

by Zacks Equity Research

Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.

Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) Q4 Earnings Lag Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -16.67% and 8.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Alpine (ALPN) Down on FDA Partial Clinical Hold on Cancer Study

by Zacks Equity Research

The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.

Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales

by Zacks Equity Research

Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics

by Zacks Equity Research

Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics have been highlighted in this Industry Outlook article.

JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs

by Zacks Equity Research

JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.

Kinjel Shah headshot

4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry

by Kinjel Shah

Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4

by Zacks Equity Research

Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.

Wall Street Analysts Predict a 25% Upside in Catalyst (CPRX): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

What Makes Catalyst (CPRX) a Good Fit for "Trend Investing"

by Zacks Equity Research

Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.

Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut

by Zacks Equity Research

Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.

Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical Studies

by Zacks Equity Research

Allogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last month.

Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges.

Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA

by Zacks Equity Research

Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.

Here's Why Momentum in Catalyst (CPRX) Should Keep going

by Zacks Equity Research

Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Wall Street Analysts See a 33% Upside in Catalyst (CPRX): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 33.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Is Aravive (ARAV) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.

ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos

by Zacks Equity Research

ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.

How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 30%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 29.6% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Catalyst's (CPRX) Q3 Earnings In Line, Revenues Beat Estimates

by Zacks Equity Research

Catalyst's (CPRX) earnings meet estimates in the third quarter of 2021 while revenues beat the same.

Jazz Pharma (JAZZ) Q3 Earnings Beat, New Drugs Drive Sales

by Zacks Equity Research

Jazz Pharma's (JAZZ) product revenues grow in the third quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.

Catalyst Pharmaceutical (CPRX) Q3 Earnings Meet Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of 0.00% and 4.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?